Key Highlights
- Smith & Nephew (LSE:SN.) spent the summer being judged on its operating margin. This week the conversation shifted to its financing, after the FTSE 100 medical technology group priced a new dollar bond and moved to retire part of an existing borrowing early.
- The refinancing arrives five weeks after the half-year report of 4 August 2026. Revenue of $3,097 million was 4.6% higher on a reported basis and 2.3% higher underlying.
- The tender results, due after the 15 September deadline, will confirm how much 2030 paper has been retired and whether the cap was reached.
The Balance Sheet Moves Into View
Smith & Nephew (LSE:SN.) spent the summer being judged on its operating margin. This week the conversation shifted to its financing, after the FTSE 100 medical technology group priced a new dollar bond and moved to retire part of an existing borrowing early.
The group announced on 10 September 2026 that it had priced $700 million of 5.750% notes maturing on 11 September 2036, with closing expected the following day. Net proceeds are stated at $690,928,000. Two days earlier it had launched a cash tender offer for up to $250 million of its 2.032% senior notes due 14 October 2030, of which $900 million is outstanding.
What the Two Announcements Do Together
The company was explicit about the connection. Proceeds from the 2036 issue will be used to fund the purchase of the 2030 notes in the tender offer and to pay related fees, with the balance going to general corporate purposes. The tender is itself conditional on the new notes offering completing on terms satisfactory to the company.
The tender expires at 5.00pm New York time on 15 September 2026 unless extended, with settlement expected on 18 September. The price is not fixed in advance: consideration will be set on 15 September by reference to a benchmark US Treasury security plus a spread of 55 basis points. Smith & Nephew may raise or lower the maximum amount and may scale back acceptances if holders tender more than the cap.
This is a refinancing rather than a Debt reduction. The new issue raises considerably more than the tender can retire, so the net effect is to push the repayment profile further out.
The Business Behind the Debt
Smith & Nephew traces its origins to a Hull pharmacy founded in 1856 and is now headquartered in Watford. It is one of the larger pure-play medical technology companies listed in London, operating through Orthopaedics, covering hips, knees, trauma and surgical robotics; Sports Medicine and Ear, Nose and Throat; and Advanced Wound Management.
Almost all of that revenue is procedure-driven, tying the group to hospital theatre capacity, clinical staffing and elective surgery volumes. The United States is its largest market and the company reports in US dollars, which makes dollar funding its natural borrowing currency.
A First Half That Cut Both Ways
The refinancing arrives five weeks after the half-year report of 4 August 2026. Revenue of $3,097 million was 4.6% higher on a reported basis and 2.3% higher underlying. Trading profit rose 8.1% to $566 million, lifting the trading profit margin 60 basis points to 18.3%. Operating profit was $448 million and adjusted Earnings Per Share rose 11.0% to 47.7 cents. The Interim Dividend was raised 4.0% to 15.6 cents.
The softer elements were cash and guidance. Trading Cash Flow fell 10.2% to $437 million and net debt stood at $3,019 million. Management cut its full-year revenue growth expectation to around 4% from around 6%, while holding trading profit growth of about 8% excluding acquisitions, free cash flow of around $800 million and adjusted return on invested Capital above 10%.
Reading the Significance
The coupon is the detail worth noting. Replacing paper struck at 2.032% with debt costing 5.750% shows the price of extending Maturity in the current rate environment, and points to a rising finance charge as older borrowing rolls off.
The Calendar Ahead
The tender results, due after the 15 September deadline, will confirm how much 2030 paper has been retired and whether the cap was reached. Attention then returns to trading, where the second half must deliver the 5.0 to 5.5% underlying growth implied by August's revised guidance.






Please wait processing your request...